AVACTA GROUP PLC

Avacta Group is advancing cancer treatment with its pre|CISION™ platform, enabling targeted chemotherapy delivery via peptide drug conjugates. Its lead therapeutic, AVA6000, shows promise in reducing systemic side effects and targeting tumours directly. With Phase 1 trials progressing and a focus on precision oncology, Avacta is poised for significant developments by 2025.

Avacta Group is advancing cancer treatment with its pre|CISION™ platform, enabling targeted chemotherapy delivery via peptide drug conjugates. Its lead therapeutic, AVA6000, shows promise in reducing systemic side effects while targeting tumours directly. With Phase 1b trials underway and data expected in 2025, Avacta is poised for significant developments in precision oncology.

Avacta Group (AIM: AVCT) pioneers cancer treatment via its pre|CISION™ platform, developing peptide drug conjugates (PDCs) to deliver chemotherapy directly to tumors, minimizing side effects. Its lead therapeutic, AVA6000, shows promise in Phase 1 trials for aggressive cancers. The pre|CISION™ platform reduces systemic toxicity, positioning Avacta as a leader in precision oncology. With over £32 million in cash reserves, Avacta faces clinical trial risks but is well-positioned for growth in 2025.

Avacta Therapeutics issues 5,930,659 new ordinary shares to settle £2.55m principal and £0.54m interest on convertible bond, reducing remaining principal to £30.60m. The bond was initially issued in Oct 2022 to fund acquisitions and working capital, with the company now focusing on drug development. The new shares are expected to be admitted to trading on AIM on 23 Oct 2024, increasing total issued share capital to 369,306,389.

Avacta Group collaborates with Tempus AI to optimize clinical development using Tempus' multimodal datasets, aiming for higher success in oncology programs.

Avacta Therapeutics partners with Tempus AI to leverage AI for oncology drug development, gaining access to Tempus's patient datasets. Avacta expands its pre|CISION® platform with new preclinical programs, AVA6103 and AVA7100, targeting tumors with minimal impact on healthy tissue. Tempus AI's financial maneuvers and technological advancements, including FDA clearance for its Tempus ECG-AF device, underscore its strategic position in precision medicine.

Avacta Therapeutics initiates AI-focused collaboration with Tempus AI to advance oncology drug development using Tempus' multimodal datasets. The partnership aims to enhance Avacta's pre|CISION® platform by analyzing tumor microenvironment and FAP activity, supporting clinical programs like AVA6103 and AVA7100. This collaboration seeks to identify optimal patient populations for Avacta's therapies, potentially accelerating clinical development.

AVA6000 demonstrates safety and efficacy in FAP-positive solid tumors, with durable RECIST responses and reduced cardiac toxicity compared to conventional doxorubicin. The pre|CISION-enabled doxorubicin shows altered pharmacokinetics, suggesting improved tumor targeting and reduced systemic side effects.

Avacta Group to present updated Phase 1a trial data of AVA6000 at 2024 ESMO Congress in Barcelona, focusing on FAP-positive solid tumours. AVA6000 is a doxorubicin peptide drug conjugate targeting the tumour microenvironment.